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and bHCG of b1 IU/L.
The thoracicmasswas targeted by biopsy butwas non-diagnostic. She
subsequently underwent a laparotomy with left salpingoophorectomy,
left pelvic lymph node dissection and removal of a 5 cm paraaortic
lymph node.With respect to her intraabdominal disease, shewas consid-
ered optimally debulked tomicroscopic disease. An intraoperative patho-
logic consultation of the pelvic mass was interpreted as a poorly
differentiatedneoplasmwith extensivenecrosis. Onpermanent histology,
an undifferentiated carcinoma with focal squamous differentiation was
diagnosed (Figs. 2A and B). In light of the elevated tumormarkers, exten-Introduction
NUT midline carcinoma is a rare aggressive carcinoma arising in
midline structures. The most common areas of diagnosis are the
head and neck region and mediastinum. There are only 62 known
cases and this is the second case describing the involvement of gyne-
cologic structures (French et al., 2004; French, 2012). This tumor is
refractory to conventional treatments, with a median survival of
6.7 months and an overall survival of 19% at 2 years(Bauer et al.,
2012). However, since the key molecular alteration is known promis-
ing research is emerging with the goal to overcome differentiation ar-
rest in these tumors.
Case
A 19 year old female presented with a three month history of an in-
crease in shortness of breath, cough, and pelvic discomfort. Chest x-ray
showed an opacity in the left superior mediastinum. A CT scan of the
chest, abdomen, and pelvis revealed masses in both the chest and
pelvis. The chest contained a solid mass measuring 11 cm×7.5 cm
within the left lung encasing the left pulmonary artery and distal
bronchial tree somewhat arising from the mediastinum. The pelvis
contained a multilobular complex mass measuring 15 cm×12 cm
at the left adnexa (Fig. 1B). She was transferred to the Gynecologic
Oncology service, Tom Baker Cancer Center, Calgary AB. Tumormarkersertahealthservices.ca (A. Ball).
ier Inc. Open access under CC BY-NC-ND lsive samplingwas performedbut did not reveal any germcell tumor com-
ponent (yolk sac, embryonal, dysgerminoma, or teratoma). A battery of
immunohistochemical markers was applied but was non informative
with the exception of diffuse p63 expression supporting squamous cell
lineage. Despite the young age, malignant transformation of a somatic
tumor overgrowing a teratoma was considered. . Other differential diag-
nosis occurring in this age group included the large cell variant of small
cell carcinoma of hypercalcemic type (diligent search failed to show typ-
ical follicles,WT1negative) and other small cellmalignant tumors such as
metastatic melanoma (S100 negative) and primitive neuroectodermal
tumor (PNET, CD99 negative). But the lack of typical morphological
features (the tumor cells were not particularly small) or immunohisto-
chemical marker negativity precluded these diagnoses.
The patient received four cycles of bleomycin, etopiside, and cis-
platin. The thoracic mass initially decreased in size from chemo-
therapy. However, ongoing investigations deemed the mass
unresectable and not amenable to bronchial stenting. Repeated at-
tempts at biopsy of the thoracic mass resulted in further necrotic
tissue and atypical cells suspicious for malignancy, but no deﬁnitive
diagnosis. She subsequently developed a pericardial effusion. The
thoracic mass continued to enlarge to virtually replace the entire
left lung, and the patient developed progressive respiratory symp-
toms (Fig. 1A). She had ongoing shortness of breath, increasing me-
diastinal deviation, and tumor invasion involving the chest wall.
She underwent a course of palliative radiation therapy to the chest
(20 Gray over 5 days) andwas started on carboplatin and paclitaxel.
The patient received only one cycle before developing febrile
neutropenia, electrolyte disturbances, and anemia. Over the subse-
quent two weeks she developed progressive cardiothoracic symp-
toms, including unstable tachyarrhythmias and hypoxemia. At this
time a decision was made to treat her palliatively. She passed
away peacefully ﬁve months after her diagnosis of cancer. Permis-
sion was granted for an autopsy.icense.
Fig. 1. A. Coronal CT image of the chest during chemotherapy treatment, indicating marked adverse change from time of diagnosis. There is encasement of the aorta and great
vessels, and occlusion of the pulmonary veins and left mainstem bronchus. The mass measures approximately 10 cm by 11 cm and there are multiple loculations of ﬂuid and
tumor contributing to the pronounced mediastinal shift. B. Coronal CT image of the abdomen and pelvis at the time of diagnosis. There is a complex multilobular pelvic mass arising
from the left ovary measuring 15 cm×12 cm. Also noted is a paraaortic nodal mass measuring 5 cm.
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num, heart, pericardium, left lung, left hemidiaphragm, left peri-renal
fat, mesenteric root, small and large intestine (Fig. 3) associated with
pericardial and pleural effusion, and left hydronephrosis. The histology
of the tumor at autopsy was identical to that of the pelvic mass with
sheets of poorly differentiated, extensively necrotic carcinoma with
small foci of abrupt squamous differentiation. Discussion of the case
and evaluation of the literature led to the possibility that the tumor
was a NUT midline carcinoma (French et al., 2003). External consulta-
tion was sought with the International Nut Midline Carcinoma Registry
at the Brigham and Woman's Hospital. The diagnosis of NUT midline
carcinomawith BRD4-NUT fusion wasmade after demonstration of dif-
fuse nuclear immunohistochemical stainingwith NUT protein (Fig. 2C),
and byﬂuorescent in situhybridization, performed as described (Fig. 2C,
inset) (Haack et al., 2009).Fig. 2. A. Non-speciﬁc sheet of medium size, slightly discohesive tumor cells with prominen
tinization indicating squamous differentiation. (H&E, 400×) C. Immunohistochemistry of tum
formalin-ﬁxed, parafﬁn-embedded sections reveals tetraploid tumor cell nuclei with fusion
signals are the normal alleles of BRD4 and NUT, respectively. Not all signals are present perDiscussion
NUT midline carcinoma (NMC) is a rare aggressive cancer of squa-
mous cell lineage arising in midline structures. NMC are not classiﬁed
according to the tissue/site of origin as with the majority of solid
tumors, but are rather deﬁned genetically. The cytogenetics of NMC
are less complex than of typical squamous cell carcinomas. The char-
acteristic cytogenetic abnormality is a reciprocal translocation of the
NUT (nuclear protein in testis, AKA Chr15orf55) gene on the long
arm of chromosome 15 with one of the BET family members, most
commonly BRD4 (also known as MCAP and HUNK1) on chromosome
19p13.1 (t(15;19)(q14;p13.1)) (Bauer et al., 2012 Sep 17). This re-
sults in a fusion oncogene (BRD4-NUT) which arrests normal cellular
differentiation (French et al., 2008). The NUT translocation can be
diagnosed using karyotype, FISH or RT-PCR. A monoclonal antibodyt nucleoli, limited nuclear variability and high mitotic activity. B. Focus of abrupt kera-
or cell nuclei showing speckled staining for NUT. Inset: Dual color, dual fusion FISH on
of NUT spanning probes (red) to BRD4 spanning probes (green). Single green and red
nucleus because these are thin sections (4 μm).
Fig. 3. Autopsy picture of the open thorax exposing extensive tumor involving the left
thorax and cardiac structures.
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application.(Haack et al., 2009). The immunohistochemical assay can
detect the NUT protein in NMC, whose expression in normal mature
adult tissue is restricted to the testis. With the use of the immuno-
histochemical assay it became clear that NMC is not restricted to
younger patients but affects all age groups (French, 2012).
NMC is often widely metastatic and unresectable when diagnosed.
All known cases of NMC have had a poor clinical course with a mean
survival of approximately nine months. The histological diagnosis is
usually that of poorly differentiated or squamous cell carcinoma
but occasionally has been classiﬁed as other tumors, e.g. thymic carci-
noma. As in our case these tumors are virtually refractory to radiation
and chemotherapy. However, growing understanding about the func-
tion of the key molecular alteration does show promising approaches
to overcome the differentiation arrest. The normal function of NUT is
hypothesized to aid chromatin compaction during spermatogenesis
and interfering with the balance of histone acetylation/deacetylation.
One means to bring the chromatin into a more relaxed state, which isassociated with increased gene transcription and differentiation, is to
block the endogenous action of histone deacytelases.
Recent research that utilizes therapeutic histone deacetylase inhibi-
tors (HDACi) to derepress differentiation of the NMC cells appears
promising. Cell lines of NUT carcinoma cells and murine models have
responded to various HDACi. Vorinostat, a HDACi, was used in the
case of a 10-year old boywith a NUTmidline carcinoma. Hewas treated
for ﬁve weeks and had an objective clinical response before toxicities
limited its continued use. After stopping the drug, the disease recurred
and he died eleven months after diagnosis. Despite the inability to
achieve cure in his case, HDACi use remains a focus of ongoing clinical
research in treating this disease (Schwartz et al., 2011).
The case presented here is a rare case of a NUT midline carcinoma
involving gynecologic structures. However her concurrent thoracic
mass posed the greater clinical challenge and was unresectable at
presentation. Despite some initial response, it became refractory to
treatment and was ultimately the cause of her rapid decline and
death. This case brings to light this rare tumor as a possible etiology
when an aggressive, poorly differentiated carcinoma is identiﬁed,
and serves an example in which the knowledge about the underlying
molecular alterations can serve as guide towards developing an effec-
tive treatment for this devastating disease.
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